千金药业：下属子公司取得药品注册证书

Group 1 - The core point of the article is that Qianjin Pharmaceutical has received approval for the registration certificate of hydrochloride rufinamide tablets from the National Medical Products Administration [1] - Qianjin Pharmaceutical's revenue composition for the first half of 2025 is as follows: 55.83% from drug production, 41.72% from drug wholesale and retail, 6.91% from other industries, 1.64% from traditional Chinese medicine materials and decoction pieces, and -6.1% from internal offsets [1] - As of the report date, Qianjin Pharmaceutical has a market capitalization of 5 billion yuan [1]